Cell-free DNA concentration and integrity as a screening tool for cancer

Indian Journal of Cancer

Volumn 50, Issue 3, 2013, Pages 175-183

  Zaher, Ebtsam R ^a   Anwar, Medhat M ^a   Kohail, Hanaa M A ^a   El Zoghby, Safinaz M ^a   Abo El Eneen, Marwa S ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cancer; cell free DNA; DNA integrity; screening

Indexed keywords

DNA;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CELL FREE SYSTEM; DNA DETERMINATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

ADULT; AGED; AREA UNDER CURVE; CELL-FREE SYSTEM; DNA; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885392318     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.118721     Document Type: Article

References (39)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society; 2008.
2. Farin K, Graça MD, William FA. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
3. Boyle P, Levin B. World cancer report 2008. IARC Non serial Publication, IARC; Lyon: International Agency for Research on Cancer; 2008. p9.
4. Freedman LS, Edwards BK, Ries LAG, Young JL, editors. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. National Cancer Institute, 2006. NIH Pub. No. 06-5873. Bethesda, MD;
5. Elattar I. Breast cancer, magnitude of the problem: Egyptian society of surgical oncology conference. Taba, Sinai, Egypt; (30 March-1 April 2005). http://www.docstoc.com/docs/44720076/Breast-Cancer-Magnitude-of-the-Problem
6. Levenson VV. Biomarkers for early detection of breast cancer: What, when, and where? Biochim Biophys Acta 2007;1770:847-56.
7. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
8. Harris R, Kinsinger LS. Principles of screening for cancer. In: Chang AE, Hayes DF, Pass HI, Stone RM, Ganz PA, Kinsella TJ, et al., editors. Oncology: An Evidence-based Approach. New York: Springer; 2006. p. 161-76.
9. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-A survey. Biochim Biophys Acta 2007;1775:181-232.
10. Laktionov PP, Tamkovich SN, Rykova EY, Bryzgunova OE, Starikov AV, Kuznetsova NP. Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids 2004;23:879-83.
11. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci 2009;46:1-24.
12. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci 2001;945:239-49.
13. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids-A promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581:795-9.
14. Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of cancer. Biochem Pharmacol 2008;76:1333-9.
15. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004;116:205-19.
16. Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ 2003;10:108-16.
17. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederry C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann NY Acad Sci 2000;906:161-8.
18. Krysko DV, Berghe TV, Herde KD, Vandenabeele P. Apoptosis and necrosis: Detection, discrimination and phagocytosis. Methods 2008; 44:205-21.
19. Sozzi G, Conte D, Leon EM, Cirincione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902-8.
20. Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis. Lung Cancer 2010;69:225-31.
21. Van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010;43:26-36.
22. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat Res 2007;635:105-17.
23. Pinzani P, Salvianti F, Pazzagli M, Orlando C. Circulating nucleic acids in cancer and pregnancy. Methods 2010;50:302-7.
24. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA: Apoptosis and active DNA release. Clin Chim Acta 2001;313:139-42.
25. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: State of the issue. Histol Histopathol 2004;19:575-83.
26. Sidransky D. Circulating DNA what we know and what we need to learn. Ann N Y Acad Sci 2000;906:1-4.
27. Leon SA, Shapiro B, Servi P, Parsons RG. A comparison of DNA and DNA-binding protein levels in malignant disease. Eur J Cancer 1981;17:533-8.
28. Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 2006;243:64-70.
29. Lecomte T, Ceze N, Dorval E, Laurent-Puig P. Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol 2010;34:662-81.
30. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, et al. Amount of DNA in plasma and cancer risk: A prospective study. Int J Cancer 2004;111:746-9.
31. Hauser S, Zahalka T, Ellinger J, Fechner G, Heukamp LC, VON Ruecker A, et al. Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer. Anticancer Res 2010;30:2785-9.
32. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 2010;12:173-80.
33. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-8.
34. Ellinger J, Müller SC, Stadler TC, Jung A, von Ruecker A, Bastian PJ. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 2011;29:124-9.
35. Jiang W, Zahurak M, Goldenberg D, Milman Y, Park HL, Westra WH, et al. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 2006;119:2673-6.
36. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006;24:4270-6.
37. Ellinger J, Bastian PJ, Ellinger N, Kahl P, Perabo FG, Büttner R, et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: A prognostic entity. Cancer Lett 2008;264:274-80.
38. Sozzi G, Conte D, Mariani L, Vullo SL, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-8.
39. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009;64:92-7.